Bioheart to launch clinical trial using adipose cells
Bioheart stated it will begin a U.S. clinical program utilizing adipose cells for congestive heart failure patients. In what it is calling the Angel trial, the Sunrise, Fla.-based company will use data from a Phase I/II trial in Mexico and clinical studies to apply to the FDA to start a Phase I study in the U.S.
Bioheart reported that the Regenerative Medicine Institute of Tijuana, Mexico, has successfully treated six congestive heart failure patients using stem cells derived from a patient’s own body fat.
“Bioheart has completed several preclinical studies demonstrating the safety and efficacy of this product including a study led by Keith March, MD, PhD, director of the Vascular and Cardiac Center for Adult Stem Cell Therapy at Indiana University," the company stated. “The adipose cells showed a tendency toward cardiomyocyte regeneration, prominent angiogenesis and reduction in the infarction size.”
Bioheart reported that the Regenerative Medicine Institute of Tijuana, Mexico, has successfully treated six congestive heart failure patients using stem cells derived from a patient’s own body fat.
“Bioheart has completed several preclinical studies demonstrating the safety and efficacy of this product including a study led by Keith March, MD, PhD, director of the Vascular and Cardiac Center for Adult Stem Cell Therapy at Indiana University," the company stated. “The adipose cells showed a tendency toward cardiomyocyte regeneration, prominent angiogenesis and reduction in the infarction size.”